Literature DB >> 2674456

Status of adjuvant therapy for colorectal cancer.

R J Mayer1, M J O'Connell, J E Tepper, N Wolmark.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2674456     DOI： 10.1093/jnci/81.18.1359

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  9 in total

Review 1.  Choosing quality of care measures based on the expected impact of improved care on health.

Authors:  A L Siu; E A McGlynn; H Morgenstern; M H Beers; D M Carlisle; E B Keeler; J Beloff; K Curtin; J Leaning; B C Perry
Journal:  Health Serv Res       Date:  1992-12       Impact factor: 3.402

Review 2.  Surgical excision alone is adequate treatment for primary colorectal cancer.

Authors:  R Hind; D R Rew; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1992-01       Impact factor: 1.891

3.  Carcinoembryonic antigen. New applications for an old marker.

Authors:  J A Norton
Journal:  Ann Surg       Date:  1991-02       Impact factor: 12.969

Review 4.  Adjuvant therapy for patients with colorectal cancer.

Authors:  G Steele
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

5.  5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.

Authors:  D Brohée
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

6.  Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D.

Authors:  Ji-Cheng Zhang; Zuo-Ren Wang; Yan-Juan Cheng; Ding-Zhong Yang; Jing-Sen Shi; Ai-Lin Liang; Ning-Na Liu; Xiao-Min Wang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 7.  Advances in the treatment of early- to late-stage colorectal cancer: 20 years of progress.

Authors:  G Steele
Journal:  Ann Surg Oncol       Date:  1995-01       Impact factor: 5.344

Review 8.  New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').

Authors:  G Blackledge
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

9.  Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis.

Authors:  S M Bentzen; I Balslev; M Pedersen; P S Teglbjaerg; F Hanberg-Sørensen; J Bone; N O Jacobsen; A Sell; J Overgaard; K Bertelsen
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.